LU93276I2 - Elotuzumab - Google Patents

Elotuzumab Download PDF

Info

Publication number
LU93276I2
LU93276I2 LU93276C LU93276C LU93276I2 LU 93276 I2 LU93276 I2 LU 93276I2 LU 93276 C LU93276 C LU 93276C LU 93276 C LU93276 C LU 93276C LU 93276 I2 LU93276 I2 LU 93276I2
Authority
LU
Luxembourg
Prior art keywords
elotuzumab
Prior art date
Application number
LU93276C
Other languages
English (en)
Original Assignee
Abbvie Biotherapeutics Inc
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38831279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU93276(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Biotherapeutics Inc, Dana Farber Cancer Inst Inc filed Critical Abbvie Biotherapeutics Inc
Publication of LU93276I2 publication Critical patent/LU93276I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
LU93276C 2006-08-07 2016-10-24 Elotuzumab LU93276I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83618506P 2006-08-07 2006-08-07
US94426207P 2007-06-15 2007-06-15
PCT/US2007/075403 WO2008019378A1 (fr) 2006-08-07 2007-08-07 Méthodes de traitement du myélome multiple mettant en œuvre des polythérapies à base d'anticorps anti-cs1

Publications (1)

Publication Number Publication Date
LU93276I2 true LU93276I2 (fr) 2016-12-27

Family

ID=38831279

Family Applications (3)

Application Number Title Priority Date Filing Date
LU93275C LU93275I2 (fr) 2006-08-07 2016-10-24 Elotuzumab
LU93276C LU93276I2 (fr) 2006-08-07 2016-10-24 Elotuzumab
LU93277C LU93277I2 (fr) 2006-08-07 2016-10-24 Elotuzumab

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LU93275C LU93275I2 (fr) 2006-08-07 2016-10-24 Elotuzumab

Family Applications After (1)

Application Number Title Priority Date Filing Date
LU93277C LU93277I2 (fr) 2006-08-07 2016-10-24 Elotuzumab

Country Status (23)

Country Link
US (4) US8632772B2 (fr)
EP (5) EP2068874B1 (fr)
JP (1) JP5340935B2 (fr)
CN (1) CN101686971B (fr)
AU (1) AU2007281684C1 (fr)
BR (1) BRPI0716647A2 (fr)
CA (1) CA2660356C (fr)
CY (5) CY1116247T1 (fr)
DK (2) DK2068874T3 (fr)
ES (2) ES2589302T3 (fr)
HR (2) HRP20150449T1 (fr)
HU (4) HUE029027T2 (fr)
IL (2) IL196919A (fr)
LT (4) LT2641601T (fr)
LU (3) LU93275I2 (fr)
MX (1) MX2009001441A (fr)
NL (1) NL300840I2 (fr)
NO (1) NO346835B1 (fr)
NZ (1) NZ574978A (fr)
PL (2) PL2068874T3 (fr)
PT (2) PT2641601T (fr)
SI (2) SI2068874T1 (fr)
WO (1) WO2008019378A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500370A (ja) * 2006-08-07 2010-01-07 ピーディーエル バイオファーマ，インコーポレイティド 多発性硬化症を処置するための抗ｃｓ１抗体を用いる組成物および方法
PL2068874T3 (pl) 2006-08-07 2015-06-30 Abbvie Biotherapeutics Inc Sposoby leczenia szpiczaka mnogiego z użyciem terapii skojarzonych opartych na przeciwciałach anty-cs1
US9096681B2 (en) * 2008-06-02 2015-08-04 Dana-Farber Cancer Institute, Inc. XBP1, CD138, and CS1 peptides
WO2010008726A1 (fr) 2008-06-16 2010-01-21 Immunogen Inc. Nouveaux effets synergiques
AU2009308516B2 (en) * 2008-10-21 2016-08-25 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
CA2773579C (fr) 2009-09-10 2019-01-15 Kyowa Kirin Co., Ltd. Medicament comprenant une composition d'anticorps liee specifiquement au recepteur de chimiokine cc4 humain (ccr4)
WO2011066351A1 (fr) * 2009-11-24 2011-06-03 Celgene Corporation Composés immuno-modulateurs pour la restauration de la sensibilité à la vitamine d dans des cellules tumorales résistantes à la vitamine d
CN102241773B (zh) * 2010-05-13 2014-05-14 四川大学 抗骨髓瘤细胞多克隆抗体及其制备方法
CA2888803A1 (fr) 2012-11-05 2014-05-08 Jooeun Bae Xbp1, cd138 et cs1, compositions pharmaceutiques qui comprennent les peptides et procedes d'utilisation de tels peptides et compositions
EP3066127A1 (fr) 2013-11-06 2016-09-14 Bristol-Myers Squibb Company Schémas posologiques immunothérapeutiques et combinaisons de ceux-ci
WO2015069785A1 (fr) * 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Combinaison d'anticorps anti-kir et d'anticorps anti-cs1 pour traiter un myélome multiple
CA2924268C (fr) * 2013-11-21 2021-05-18 F. Hoffmann-La Roche Ag Anticorps anti-alpha-synucleine et leurs methodes d'utilisation
KR20170042598A (ko) * 2014-08-22 2017-04-19 셀진 코포레이션 항체와 조합된 면역조절 화합물을 이용하여 다발성 골수종을 치료하는 방법
WO2016049022A1 (fr) * 2014-09-23 2016-03-31 Board Of Trustees Of Michigan State University Compositions et procédés de modulation d'une réponse immunitaire
US10365280B2 (en) 2014-10-02 2019-07-30 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating malignancies
EP3212668B1 (fr) 2014-10-31 2020-10-14 AbbVie Biotherapeutics Inc. Anticorps anti-cs1 et conjugués anticorps-médicament
US10302644B2 (en) 2014-11-04 2019-05-28 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating multiple myeloma
CN107249632A (zh) 2014-12-04 2017-10-13 百时美施贵宝公司 用于治疗癌症(骨髓瘤)的抗cs1与抗pd‑1抗体的组合
PT3294769T (pt) 2015-05-13 2021-04-13 Morphosys Ag Tratamento para mieloma múltiplo (mm)
EP3313528B1 (fr) 2015-06-29 2021-08-04 Bristol-Myers Squibb Company Schémas posologiques immunothérapeutiques à base de pomalidomide et d'un anticorps anti-cs1 pour le traitement du cancer
CN109498799A (zh) * 2016-03-13 2019-03-22 曹帅 一种用于治疗骨髓增生、骨癌的药物组合物及其用途
WO2018182529A1 (fr) * 2017-03-29 2018-10-04 Agency For Science, Technology And Research Anticorps anti-oligosaccharide
WO2019104001A1 (fr) * 2017-11-22 2019-05-31 Hillstream Biopharma Inc. Nanoparticules polymères comprenant du bortézomib
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
KR20220092578A (ko) 2019-11-05 2022-07-01 브리스톨-마이어스 스큅 컴퍼니 M-단백질 검정 및 이의 용도
CN115368462B (zh) * 2022-07-19 2026-01-02 合肥天港免疫药物有限公司 双特异性抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112969A (en) 1994-03-17 2001-05-20 Baxter Int Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
AU5930396A (en) 1995-05-25 1996-12-11 Baxter International Inc. Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
CN102342938B (zh) * 2002-05-17 2014-08-20 细胞基因公司 用于治疗和控制实体瘤的方法及组合物
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
WO2006048877A2 (fr) * 2004-11-04 2006-05-11 Fibron Limited Traitement des pathologies malignes du lymphocyte b
JP2010500370A (ja) * 2006-08-07 2010-01-07 ピーディーエル バイオファーマ，インコーポレイティド 多発性硬化症を処置するための抗ｃｓ１抗体を用いる組成物および方法
PL2068874T3 (pl) 2006-08-07 2015-06-30 Abbvie Biotherapeutics Inc Sposoby leczenia szpiczaka mnogiego z użyciem terapii skojarzonych opartych na przeciwciałach anty-cs1
US20080095768A1 (en) 2006-08-07 2008-04-24 Pdl Biopharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells

Also Published As

Publication number Publication date
HUS1600043I1 (hu) 2016-12-28
US20140322201A1 (en) 2014-10-30
HRP20150449T1 (xx) 2015-06-05
PT2641601T (pt) 2016-10-14
AU2007281684B2 (en) 2013-05-16
LT2641601T (lt) 2016-10-10
EP2942057A1 (fr) 2015-11-11
PL2068874T3 (pl) 2015-06-30
CY1116247T1 (el) 2017-02-08
HK1129853A1 (en) 2009-12-11
BRPI0716647A2 (pt) 2017-05-16
EP2641601B8 (fr) 2016-09-21
DK2068874T3 (da) 2015-04-27
HUS1600044I1 (hu) 2016-12-28
NL300840I2 (fr) 2017-01-03
US20170342150A1 (en) 2017-11-30
US20160137735A1 (en) 2016-05-19
PL2641601T3 (pl) 2017-01-31
NZ574978A (en) 2012-08-31
HUE029027T2 (en) 2017-01-30
CA2660356C (fr) 2016-04-05
NO346835B1 (no) 2023-01-23
SI2068874T1 (sl) 2015-06-30
HUS1600045I1 (hu) 2016-12-28
EP2641601A1 (fr) 2013-09-25
MX2009001441A (es) 2009-07-06
LTC2068874I2 (lt) 2018-11-12
DK2641601T3 (en) 2016-08-22
EP2641601B1 (fr) 2016-07-06
ES2589302T3 (es) 2016-11-11
CY2016037I1 (el) 2017-07-12
CN101686971A (zh) 2010-03-31
IL196919A (en) 2016-03-31
LTPA2016030I1 (lt) 2016-11-10
CA2660356A1 (fr) 2008-02-14
CY2016036I1 (el) 2017-07-12
JP5340935B2 (ja) 2013-11-13
LU93277I2 (fr) 2016-12-27
PT2068874E (pt) 2015-05-21
EP2068874A1 (fr) 2009-06-17
US8632772B2 (en) 2014-01-21
JP2010500371A (ja) 2010-01-07
HRP20161284T1 (hr) 2016-12-16
AU2007281684A1 (en) 2008-02-14
LTPA2016031I1 (lt) 2016-11-10
ES2535437T3 (es) 2015-05-11
US20080152646A1 (en) 2008-06-26
CY2016036I2 (el) 2017-07-12
NO20090968L (no) 2009-04-30
EP3115049A1 (fr) 2017-01-11
LU93275I2 (fr) 2016-12-27
LTPA2016029I1 (lt) 2016-11-10
AU2007281684C1 (en) 2013-12-19
CY2016038I1 (el) 2017-07-12
IL196919A0 (en) 2009-11-18
IL243933A0 (en) 2016-04-21
SI2641601T1 (sl) 2016-11-30
WO2008019378A1 (fr) 2008-02-14
EP2641600A1 (fr) 2013-09-25
EP2068874B1 (fr) 2015-01-28
CY1117992T1 (el) 2017-05-17
CN101686971B (zh) 2013-09-11

Similar Documents

Publication Publication Date Title
LU93275I2 (fr) Elotuzumab
EP2087096A4 (fr) Cyanobacterie modifiee
DE602006004717D1 (de) Kapselperforationsmodul
DE602007002544D1 (de) Nuancierungsmittel
DE602007008423D1 (de) Flüssigkeitshärtung
DE602007009267D1 (de) Reifenaufblasverfahren
DE602007003893D1 (de) Kippambossanordnung
AT504580A3 (de) Scan-einrichtung
DE602007012130D1 (de) Modifizierte flavin-adenin-dinucleotid-abhängige glucose-dehydrogenase
DE602007006947D1 (de) Pyridopyrimidinonderivate
DE602007000258D1 (de) Kassetteneinspannmechanismus
DE602007001280D1 (de) Getränkeextraktor
DE602007008400D1 (de) Kaliummonopersulfatlösungen
DE602006020192D1 (de) Riemenscheibenanorndung
DE502007001629D1 (de) Rfahren
ATE546437T1 (de) Aminomethyl-4-imidazole
DE502007000218D1 (de) nsetzungen
DE502007002453D1 (de) Kunstoffverdichtergehäuse
DE602007001098D1 (de) Spindelmäheinheit
DE602007000501D1 (de) Breitbandrichtkoppler
DE602007004080D1 (de) Tintenstrahlaufnehmer
DE602007007460D1 (de) Sehkrafttestsystem
DE502007000361D1 (de) Stanznieteinheit
DE602007000333D1 (de) Napfbefestigungsvorrichtung
DE602006019150D1 (de) Riemenscheibenanorndung